Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
Psyence Biomedical Ltd. - Common Shares (PBM)
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that the Bellberry Human Research Ethics Committee (HREC) has formally approved the use of PsyLabs’ psilocybin product (NPX5) in the Company’s ongoing Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in patients with cancer. This approval highlights the Company’s distinct evolution toward becoming one of the few vertically integrated psychedelic enterprises with multiple assets across drug and clinical development. With an investment in Psylabs, significant clinical assets and a strong cash reserves balance of approximately USD $9.5 million, the Company is now positioned as one of the most differentiated companies in the emerging global psychedelics sector with the cash balance to execute
Show less
Read more
Impact Snapshot
Event Time:
PBM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBM alerts
High impacting Psyence Biomedical Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
PBM
News
- Court sides with psychedelic biotech, over hedge fund [Advisor.ca (Canada)]Advisor.ca
- Court sides with psychedelic biotech, over hedge fund [Investment Executive - News]Investment Executive - News
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock SplitGlobeNewswire
- Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026GlobeNewswire
- Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective DateGlobeNewswire
PBM
Sec Filings
- 1/29/26 - Form 6-K
- 1/27/26 - Form 6-K
- 1/14/26 - Form 6-K
- PBM's page on the SEC website